A recent Spanish study concludes that CT-P13, a biosimilar of reference infliximab that has been approved in Korea, the European Union, and the United States, is efficacious and well tolerated in patients with moderate to severe Crohn’s disease (CD) or ulcerative colitis (UC).
A recent Spanish study published in Digestive Diseases and Sciences concludes that CT-P13 (Remsima, Inflectra), a biosimilar of reference infliximab (Remicade) that has been approved in Korea, the European Union, and the United States, is efficacious and well tolerated in patients with moderate to severe Crohn’s disease (CD) or ulcerative colitis (UC).
Federico Argüelles-Arias, MD, PhD, and colleagues conducted a preliminary observational trial in patients in Spain with inflammatory bowel disease who were either naïve to anti-tumor necrosis factor (anti-TNF) treatment or who were switched from reference infliximab to CT-P13. Efficacy and safety were assessed at months 3 and 6 of therapy in both the treatment-naïve patients and in switched patients who were in remission at the time of the switch. All patients received intravenous corticosteroids and antihistamines as premedication prior to the infusion treatment.
A total of 80 CD patients and 40 UC patients were included in the study. Among the CD patients, 13 (16.25%) were naïve to anti-TNF and 67 (83.75%) were switched from reference infliximab to CT-P13. At the time of the switch, 56 of the 67 patients (83.5%) were in remission. Median duration of ongoing reference infliximab treatment at the start of the study was 297 weeks.
Over the course of the study, 6 participants were excluded (1 did not attend follow-ups, 3 had adverse events, 1 had no response to treatment, and 1 was referred to surgery).
Of the 40 UC patients, 9 (22.5%) were naïve to anti-TNF (6 of these 9 patients had treatment with steroids), and 31 (77.5%) were switched from reference infliximab to CT-P13. A total of 25 out of 31 of the UC switched patients were in remission at the time of the switch.
The researchers found that 87.5% of switched patients with CD who were previously in remission remained so, and 66.7% and 50% of treatment-naïve patients with CD reached remission at months 3 and 6, respectively.
In switched patients with UC, 92% and 91.3% of patients in remission at the time of the switch maintained remission at 3 and 6 months, respectively. In treatment-naïve patients with UC, the remission rates were 44.4% and 66.7% at months 3 and 6, respectively.
The researchers report that there were serious adverse events (AEs) in 9 patients (7.5%), 6 of whom discontinued treatment due to AEs, which included the following:
The researchers concluded that CT-P13 was efficacious and well tolerated in patients with CD or UC. “Response was maintained in 84% of switched CD and in 91.3% of switched UC patients, and clinical remission was reached in 50% of naïve CD and 70% of naïve UC patients,” they said, demonstrating the effectiveness and safety of CT-P13 at 3 and 6 months. However, continuing assessment of response in these patients over a longer period is necessary.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.